Published • loading... • Updated
FDA Grants Priority Review to Imfinzi-Enfortumab Vedotin Regimen for Muscle-Invasive Bladder Cancer
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FDA Grants Priority Review to Imfinzi-Enfortumab Vedotin Regimen for Muscle-Invasive Bladder Cancer
As reported on PharmaBiz, the FDA has accepted AstraZeneca’s supplemental Biologics License Application for durvalumab plus neoadjuvant enfortumab vedotin in patients with muscle-invasive bladder cancer who cannot receive or have chosen not to receive cisplatin-based chemotherapy. The US Food and Drug Administration has granted Priority Review to AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
